Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer

• 成果类型: Article
• 署名作者: Sushentsev, Nikita; Hamm, Gregory; Manavaki, Roido; McLean, Mary A.; Birchall, Jonathan; Soloviev, Dmitry; Lewis, David Y.; Aloj, Luigi; Flint, Lucy; Zakirov, Aleksandr; Mills, Ian G.; Gnanapragasam, Vincent J.; Warren, Anne Y.; Barry, Simon T.; Goodwin, Richard J. A.; Gallagher, Ferdia A.; Barrett, Tristan
• 署名单位: University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; AstraZeneca; University of Glasgow; University of Cambridge; University of Oxford; Queens University Belfast; Aarhus University; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; AstraZeneca
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.2502423122
• 发表日期: 2025-07-01
• 页码: e2502423122
• 关键词: prostate cancer; cancer metabolism; mri; nuclear medicine; spectroscopy; C-11-ACETATE; pet

摘要

Cribriform prostate cancer (crPCa) is associated with poor clinical outcomes, yet its accurate detection remains challenging due to the poor sensitivity of standard- of- care diagnostic tools. Here, we use untargeted spatial metabolomics to identify fatty acid biosynthesis as a key metabolic pathway enriched in crPCa epithelium. We also show that imaging tumor copy differentiates cribriform from noncribriform intermediate- risk prostate cancers in two prospective patient cohorts. These findings support the feasibility of using clinical metabolic imaging techniques as adjunctive tools for improving crPCa detection in clinical practice, with prospective studies in larger cohorts warranted to obtain definitive results.